FelineGuard FeLV

Country: Australia

Language: English

Source: APVMA (Australian Pesticides and Veterinary Medicines Authority)

Active ingredient:

FELINE LEUKAEMIA VIRUS - INACTIVATED

Available from:

ZOETIS AUSTRALIA PTY LTD

Pharmaceutical form:

VACCINE OR ANTISERA

Composition:

FELINE LEUKAEMIA VIRUS - INACTIVATED VACCINE-VIRAL Active 0.0 U

Units in package:

10 x 1mL; 25 x 1mL

Class:

VM - Veterinary Medicine

Therapeutic area:

IMMUNOTHERAPY

Product summary:

Poison schedule: 0; Withholding period: ; Host/pest details: CAT - OVER 9 WEEKS OLD - FELINE: [FELINE LEUKAEMIA VIRUS]

Authorization status:

Registered

Authorization date:

2023-07-01

Patient Information leaflet

PRODUCT NAME:
APVMA APPROVAL NUMBER:
FELINEGUARD FELV
80322/100621
LABEL NAME:
FelineGuard FeLV Vaccine for Cats
SIGNAL HEADINGS:
FOR ANIMAL TREATMENT ONLY
Each 1 mL dose contains inactivated Feline Leukaemia Virus (FeLV)
subtypes A, B and C
(Kawakami-Theilen strain) including gp70 sub-unit antigen, inducing
anti-gp70 antibodies
GMT*
≥
8.1 Log
2
.
CONSTITUENT
STATEMENTS:
For active immunisation of healthy susceptible cats from 9 weeks of
age to reduce the
number of cats infected with FeLV and presenting clinical signs of the
related disease.
Prevention of infection is also associated with protection against
related clinical disease.
CLAIMS:
10 x 1mL dose vials
25 x 1mL dose vials
NET CONTENTS:
DIRECTIONS FOR USE:
RESTRAINTS:
Do not vaccinate pregnant and lactating cats.
Do not vaccinate FeLV antigen positive cats. A test for the presence
of FeLV before
vaccination is recommended.
CONTRAINDICATIONS: RLP APPROVED
Only healthy animals should be vaccinated.
No data are available for the efficacy of the product in the presence
of maternally
derived antibodies.
Vaccination is of no known therapeutic value in cats with existing
FeLV infection, nor will
it alter the natural course of disease.
No information is available on the safety and efficacy of this vaccine
when used with
any other veterinary medicinal product except FelineGuard 3 (APVMA
66311). See
General Directions.
PRECAUTIONS:
SIDE
EFFECTS:
Following the first subcutaneous administration in the target species,
transient
increases in temperature are very common (up to 40.5°C after
administration of an
overdose). Such temperature rises are expected to be of short duration
(resolves
within 48 hours). Frequency and duration of any temperature rise is
usually reduced
with subsequent vaccinations.
When administered concurrently or simultaneously with FelineGuard 3,
transient
increases in temperature (up to 40.5°C) are common following first
vaccination,
lasting up to 5 days.
Small subcutaneous swellings at the injection site (diameter usually
less than 10
mm, max